상세정보
- |Home >
- 상세정보
부가기능
GSK's Big Push To Maintain Its Respiratory Reign GlaxoSmithKline is counting on new products like Breo Ellipta and Anoro Ellipta to extend its legacy in respiratory disease beyond Advair Diskus, which could face generic competition within the next five years. But GSK may need to wage a battle on the reimbursement front before it can claim commercial success - a challenge highlighted by Express Scripts'decision to put Advair and Breo on its not-covered list for 2014
기사 상세정보
소장정보
- 소장정보
| No. | 권호·제본정보 보기 | 소장처 | 소장사항 | 청구기호 | 구독 | 최근입수호 |
|---|---|---|---|---|---|---|
| 1 | 중앙도서관/3층 외국학술지지원센터/ | 610 I35 | 구독중단 | v.34 no.11 |
하단메뉴
